Navigation Links
Delcath to Webcast Management's Presentation at Annual Meeting of Stockholders

NEW YORK, May 21, 2012 /PRNewswire/ -- Delcath Systems, Inc. (Nasdaq: DCTH) will host a live webcast of management's presentation to shareholders at the Company's annual stockholder meeting on May 23, 2012 at 10:00 a.m ET at The Michelangelo Hotel in New York City. The presentation will commence at approximately 10:15 a.m ET.

To listen to the live webcast and view slides of the presentation during or after the event, please visit the Investor Relations section of the Company's website at A replay will be available for ninety days after the event.

About Delcath SystemsDelcath Systems, Inc. is a development stage specialty pharmaceutical and medical device company focused on oncology. Delcath's proprietary system for chemosaturation is designed to administer high dose chemotherapy and other therapeutic agents to diseased organs or regions of the body, while controlling the systemic exposure of those agents. The Company's initial focus is on the treatment of primary and metastatic liver cancers. In 2010, Delcath announced that its randomized Phase III clinical trial for patients with metastatic melanoma in the liver had successfully achieved the study's primary endpoint of extended hepatic progression-free survival. The Company also completed a multi-arm Phase II trial to treat other liver cancers. The Company obtained authorization to affix a CE Mark for the Delcath Hepatic CHEMOSAT® delivery system in April 2011 and for the second generation hemofiltration cartridge for CHEMOSAT in April 2012. The right to affix the CE mark allows the Company to market and sell the CHEMOSAT system in Europe. The Company has not yet received FDA approval for commercial sale of its system in the United States. The Company continues with the preparation of its NDA submission and intends to seek FDA approval for commercial sale of its chemosaturation system with melphalan. For more information, please visit the Company's website at

The Private Securities Litigation Reform Act of 1995 provides a safe harbor for forward-looking statements made by the Company or on its behalf. This news release contains forward-looking statements, which are subject to certain risks and uncertainties that can cause actual results to differ materially from those described. Factors that may cause such differences include, but are not limited to, uncertainties relating to: the future initial launch and distribution of the CHEMOSAT system in Europe, CE Marking for the Generation Two system and the timing of our commercial launch in Europe, the time required to build inventory and establish commercial operations in Europe, adoption, use and resulting sales, if any, for the Hepatic CHEMOSAT delivery system in the EEA, our ability to successfully commercialize the chemosaturation system and the potential of the chemosaturation system as a treatment for patients with terminal metastatic disease in the liver, acceptability of the Phase III clinical trial data by the FDA, our ability to address the issues raised in the Refusal to File letter received from the FDA and the timing of our re-submission of our NDA, re-submission and acceptance of the Company's NDA by the FDA, approval of the Company's NDA for the treatment of metastatic melanoma to the liver, adoption, use and resulting sales, if any, in the United States, approval of the current or future chemosaturation system for other indications, actions by the FDA or other foreign regulatory agencies, our ability to obtain reimbursement for the CHEMOSAT system, our ability to successfully enter into distribution and strategic partnership agreements in foreign markets and the corresponding revenue associated with such foreign markets, uncertainties relating to the results of research and development projects and future clinical trials, and uncertainties regarding our ability to obtain financial and other resources for any research, development and commercialization activities. These factors, and others, are discussed from time to time in our filings with the Securities and Exchange Commission. You should not place undue reliance on these forward-looking statements, which speak only as of the date they are made. We undertake no obligation to publicly update or revise these forward-looking statements to reflect events or circumstances after the date they are made.Contact Information: 

Investor Contact: 

Media Contact:Doug Sherk/Gregory Gin

Janine McCargoEVC Group

EVC Group415-568-4887/646-445-4801



SOURCE Delcath Systems, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Delcath Highlights First Quarter 2012 And Recent Accomplishments
2. Delcath Systems, Inc. Secures $20 Million Credit Facility
3. Delcath Announces Agreement With Istituto Nazionale Tumori Fondazione G. Pascale for Further Expansion of CHEMOSAT in Italy
4. Delcath Announces Agreement with Instituto Oncologico Baselga for Launch of CHEMOSAT in Spain
5. Delcath Announces Agreement With Institut Gustave Roussy for Launch of Hepatic CHEMOSAT Delivery System in France
6. Delcath Announces First CHEMOSAT Procedures in Germany
7. Delcath Announces Agreement With University Medical Center Schleswig-Holstein for Use of Its Hepatic CHEMOSAT Delivery System
8. Delcath CHEMOSAT Presented as Innovative Treatment for Liver Metastases by European Institute of Oncology
9. Delcath Receives Regulatory Approval to Commercialize Hepatic CHEMOSAT® Delivery System in Australia
10. Delcaths Ireland Operations Achieves ISO 13485 Certification
11. Delcath Announces Agreement With the Frankfurt University Hospital for Launch of Hepatic CHEMOSAT Delivery System in Germany
Post Your Comments:
(Date:10/12/2015)... , Oct. 12 2015 ... the addition of the "Personalized Medicine, ... 2019 - Strategic Analysis of Industry Trends, ... their offering. --> ) ... "Personalized Medicine, Targeted Therapeutics and Companion Diagnostic ...
(Date:10/12/2015)... -- To help address the growing opioid epidemic in the ... Board of Directors is calling for a comprehensive ... the tracking of opioid prescription use; research funding for ... abuse treatment programs. David Ring , MD, ... "The new , AAOS Information Statement on Opioid Use, ...
(Date:10/12/2015)... Minn. , Oct. 12, 2015 Device ... a need to help integrate these devices into existing ... of ergonomic healthcare mounting and mobility solutions, has launched ... lightest cart yet, for a wide array of laptops ... Cart SV10 was developed exclusively for Microsoft Surface and ...
Breaking Medicine Technology:
(Date:10/12/2015)... (PRWEB) , ... October 13, 2015 , ... North American ... (IBC) at the 2015 IBC National Meeting in Rosemont, IL on October 4th. ... dedication, quality, and standards of excellence that customers have come to expect from members ...
(Date:10/12/2015)... ... October 12, 2015 , ... ... 19, 2015, high school aged female athletes, particularly in the area of track ... motion and mechanical overuse injuries than male peers in the same age group. ...
(Date:10/12/2015)... ... October 12, 2015 , ... The American Society of Clinical ... professional education and clinical training in a health care discipline. , Many ... such as: losing weight, managing pain, or stopping smoking, etc. Frequently, extravagant statements ...
(Date:10/12/2015)... ... 12, 2015 , ... The Horizon Foundation for New Jersey has awarded $846,600 ... and enhancing the quality of life in the Garden State. The grants, representing the ... , The charitable arm of Horizon Blue Cross Blue Shield of New Jersey, ...
(Date:10/12/2015)... USA (PRWEB) , ... October 12, 2015 , ... ... personal audio products, will present the latest version of Companion Mics, the CM•4 ... audiometry, at the European Union of Hearing Aid Acousticians’ (EUHA) 60th Annual Congress ...
Breaking Medicine News(10 mins):